Goldfinch Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
Phase 2
Terminated
- Conditions
- NephritisNephrosisFocal Segmental NephrosisGlomerulonephritisKidney DiseasesGlomerulosclerosisLipoid Urologic Disease
- Interventions
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Goldfinch Bio, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04950114
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Southeast Renal Research Institute, Chattanooga, Tennessee, United States
🇺🇸Academic Medical Research Institute (AMRI), Los Angeles, California, United States
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
Phase 1
Completed
- Conditions
- Diabetes MellitusKidney DiseasesDiabetes ComplicationsDiabetic NephropathiesEndocrine System Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Goldfinch Bio, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04880291
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
Phase 2
Terminated
- Conditions
- Diabetes ComplicationsGlomerulonephritisKidney DiseasesGlomerulosclerosis, Focal SegmentalNephrosis, LipoidUrologic DiseasesNephrosisDiabetic NephropathiesDiabetes MellitusEndocrine System Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Goldfinch Bio, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT04387448
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸North American Research Institute, San Dimas, California, United States
🇺🇸DaVita Hartford North, Hartford, Connecticut, United States
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
Terminated
- Conditions
- Glomerulosclerosis, Focal SegmentalDiabetic NephropathiesMinimal Change Disease
- Interventions
- Other: Diabetic Nephropathy (DN)Other: FSGS/TR-MCD
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Goldfinch Bio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04235621
- Locations
- 🇺🇸
St. Clair Nephrology, Roseville, Michigan, United States
🇺🇸DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸DaVita Pelican Point Dialysis, Las Vegas, Nevada, United States
FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Goldfinch Bio, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT03970122
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath